Jane S. Ricciuti, RPh, MS

Disclosures

July 13, 2004

In This Article

Nonsteroidal Anti-inflammatory Agents

Mobic
(meloxicam) Oral Suspension

Manufacturer: Boehringer Ingelheim

Drug Approval Classification: Original New Drug Application (Approval Date: 6/1/04)

New Dosage Form: This new drug application provides for the use of Mobic (meloxicam) Oral Suspension 7.5 mg/5 mL for the relief of the signs and symptoms of osteoarthritis.

Reference

Mobic (meloxicam) Oral Suspension Labeling

Medscape DrugInfo

Mobic (meloxicam) Oral Suspension

Comments

3090D553-9492-4563-8681-AD288FA52ACE
Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.

processing....